Yes — I reviewed the full 6-page manuscript. 

### My assessment for an IEEE conference

**Overall technical relevance: 8/10**
**Current conference readiness: ~6.5/10**
**Potential after revision: ~8–8.5/10**

The topic is clearly within the scope of an IEEE AI/ML, computer vision, biomedical engineering, or healthcare-AI conference. The paper proposes an EfficientNetB0-based brain-tumor classification pipeline with TTA and an RF/XGBoost/SVM embedding ensemble, evaluated using 5-fold stratified CV on 7,023 MRI images. 

### What is already strong

1. **Clear experimental question** — you are not simply saying "our model gets 97%." The paper emphasizes the reliability of evaluation through 5-fold CV. 
2. **Good methodology** — two-stage EfficientNet fine-tuning, class weighting, TTA, and embedding-based ensemble are reasonably well motivated. 
3. **Useful comparison** — CNN, CNN+TTA, and RF/XGB/SVM ensemble are directly compared. 
4. **Interpretability included** — Grad-CAM is a nice addition for a medical-imaging conference paper. 
5. **You openly acknowledge limitations**, especially the major issue that CV is performed at the image level because patient IDs aren't available. 

### But there is one BIG issue

Your **novelty is currently somewhat weak**.

EfficientNet + classical ML ensemble + TTA is not, by itself, a particularly novel architecture. And your own related work shows that this dataset already has results around 98–99% using other approaches, including Swin-Tiny at 99.24%. 

So I would **not** position the paper as:

> "We developed a superior brain tumor classification model."

Instead, the stronger contribution is:

> **A reliability-focused evaluation framework for brain-tumor MRI classification, investigating whether TTA and embedding-level ensemble learning provide consistent performance under cross-validation rather than relying on a single favorable train/test split.**

That framing is much more defensible.

### Biggest things I would fix before IEEE submission

| Area                        | Current                      | Priority  |
| --------------------------- | ---------------------------- | --------- |
| Research relevance          | Strong                       | —         |
| Experimental design         | Good                         | —         |
| Novelty                     | Moderate                     | 🔴 High   |
| Dataset methodology         | Needs stronger justification | 🔴 High   |
| Patient-level leakage       | Acknowledged but unresolved  | 🔴 High   |
| Statistical analysis        | Limited                      | 🟠 High   |
| Baseline/ablation           | Not sufficient               | 🔴 High   |
| Explainability              | Good start                   | 🟠 Medium |
| Writing                     | Generally good               | 🟠 Medium |
| References                  | Needs verification/cleanup   | 🟠 Medium |
| IEEE conference suitability | Yes                          | —         |

### The most important improvement

I would add **ablation experiments**.

At minimum:

* EfficientNetB0 baseline
* EfficientNetB0 + class weighting
* EfficientNetB0 + augmentation
* EfficientNetB0 + fine-tuning
* EfficientNetB0 + TTA
* EfficientNetB0 embedding + RF
* EfficientNetB0 embedding + XGBoost
* EfficientNetB0 embedding + SVM
* RF + XGBoost + SVM ensemble

Then show **mean ± std across the same 5 folds**.

Right now, the paper tells me that TTA achieves 97.74% and the ensemble achieves 97.36%, but it doesn't sufficiently establish **which component actually contributes to the improvement**. 

### Another important issue: your dataset

This sentence is potentially dangerous:

> "We merge the Training and Testing folders and re-split the whole thing..."

You need to be extremely careful here. 

Because later you explicitly acknowledge that there are no patient IDs and therefore possible near-duplicate images across folds. 

For an IEEE reviewer, this could become the **main criticism**:

**"Does the reported 97.74% actually represent generalization to unseen patients?"**

If possible, I would strongly recommend finding a version of the dataset with patient identifiers or performing duplicate/near-duplicate detection before the final experiments.

### Also fix this claim

Your conclusion currently says:

> "a reasonable step toward a genuinely useful AI-assisted screening tool." 

I'd tone this down.

Because your own limitations state that:

* it's 2D slice classification,
* patient-level leakage cannot be excluded,
* there is no external validation,
* the data comes from limited institutions/scanners. 

So claiming usefulness as a screening tool is a little ahead of the evidence.

### My conference-review style score

If I were evaluating the **current version**:

* **Relevance:** 9/10
* **Technical quality:** 7.5/10
* **Experimental evaluation:** 7/10
* **Novelty:** 6/10
* **Clarity:** 8/10
* **Reproducibility:** 7/10
* **Medical validity:** 6/10
* **Overall:** **~7/10**

So **yes, I think it is worth targeting an IEEE conference**, but I would revise it before submission rather than submit this exact version.

The paper's strongest selling point isn't the **97.74% accuracy**. It's the **cross-validated, reliability-oriented evaluation of a hybrid CNN/TTA/embedding-ensemble pipeline**, especially given how many existing studies on this benchmark rely on a single split. 

If you want, I can next do a **strict IEEE reviewer-style review** section-by-section (Abstract → Introduction → Related Work → Methodology → Results → Discussion → Limitations → References) and give you the **exact changes needed to push this toward an 8+/10 conference paper**.
